AstraZeneca partners with RNA-modifying biotech Accent Therapeutics

published 04.06.2020 08:00

Image of article 'AstraZeneca partners with RNA-modifying biotech Accent Therapeutics'

In a first for RNA-modifying drugs, AstraZeneca partners with startup Accent Therapeutics Drug giant AstraZeneca is moving deeper into RNA-based therapies with a new partnership with the startup Accent Therapeutics, which is hoping to make therapies by manipulating enzymes that subtly change RNA.

It may be the first partnership a pharmaceutical company has forged with a company working on the concept, which has already attracted a lot of attention and investment.